ReviewLa Radiologia medica2025
Does arterial spin labelling represent a valid alternative to other MR perfusion techniques in neuro-oncology?
Review in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intraventricular meningiomas show size-dependent increases in peak ASL-MRI perfusion reflecting vascular heterogeneity.Journal of neuro-oncology · 2026Article
- ASLNet: an explainable deep learning framework for glioma grading and survival prediction.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review examines the distinctive role of arterial spin labelling (ASL) in neuro-oncology. ASL is a completely non-invasive MRI technique that quantifies cerebral perfusion without exogenous contrast agents, making it an attractive alternative to dynamic susceptibility contrast (DSC) and dynamic contrast-enhanced (DCE) perfusion-particularly WHEN gadolinium cannot be administered or when serial follow-up studies are required. Unlike DSC, ASL is immune to magnetic susceptibility artefacts, and, unlike DCE, it does not demand lengthy acquisitions or complex post-processing. The available evidence indicates that ASL performs well in grading gliomas and in characterizing brain metastases, lymphomas, and meningiomas. Its superiority over other perfusion methods becomes most apparent in longitudinal follow-up of cerebral gliomas, where it reliably tracks haemodynamic changes, and in assessing tumour-related conditions such as epilepsy and paraneoplastic syndromes. Overall, ASL offers a repeatable and dependable assessment of tumour perfusion and vascularity, thereby supporting more accurate diagnosis, grading, and treatment monitoring in neuro-oncology.
Indexed as
Identifiers
40663200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.